Clearmind Medicine Shares Rise 51% After Type A FDA Meeting
10 January 2024 - 3:19PM
Dow Jones News
By Chris Wack
Clearmind Medicine shares were up 51% to $3.12 after the company
completed a Type A meeting with the U.S. Food and Drug
Administration to discuss its clinical trial of its proprietary
MEAI-based, CMND-100 compound, for the treatment of alcohol-use
disorder treatment using its novel psychedelic-based therapy.
The stock hit its 52-week low of $1.92 on Monday, and is down
98% in the past 12 months.
The biotechnology company said the meeting was "informative and
productive, and we're eager to advance the U.S. regulatory
process."
The active ingredient in CMND-100 is MEAI
(5-methoxy-2-aminoindane), a novel psychoactive molecule that has
been reported to reduce the desire to consume alcoholic beverages
while exerting a euphoric alcohol-like experience.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 10, 2024 10:04 ET (15:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.